Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present a brief corporate overview and provide an update on its AbbVie partnered programs during the Credit Suisse 24th Annual Healthcare conference on November 10, at 11:00 am MST. The presentation will include a question and answer session.
A live webcast and replay of the presentation session and Q&A can be accessed by visiting the “Calendar of Events” section on the “Investors” page of Enanta’s website at www.enanta.com. The replay webcast will be available following the presentation and will be archived for approximately 30 days.
About Enanta
Enanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases. Enanta has
developed novel protease and NS5A inhibitors that are members of the
direct-acting-antiviral (DAA) inhibitor classes designed for use against
the hepatitis C virus (HCV). Enanta’s protease inhibitors partnered with
AbbVie include paritaprevir, which is contained in AbbVie’s marketed DAA
regimens for HCV, and ABT-493, Enanta’s next-generation protease
inhibitor completing phase 2 development in combination with ABT-530,
AbbVie’s next-generation NS5A inhibitor. Enanta also has a program to
develop a host-targeted antiviral (HTA) inhibitor class for HCV targeted
against cyclophilin, as well as another DAA program to develop
nucleotide polymerase inhibitors. In addition, Enanta has a preclinical
program in non-alcoholic steatohepatitis, or NASH, which is a condition
that results in liver inflammation and liver damage caused by a buildup
of fat in the liver.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151102005187/en/
Contacts:
Carol Miceli, 617-607-0710
cmiceli@enanta.com